- Two children have died after receiving Novartis' (NYSE:NVS) spinal muscular atrophy gene therapy Zolgensma (onasemnogene abeparvovec), STAT reported.
- The deaths occurred in Russia and Kazakhstan.
- The children died about five to six weeks after the one-time infusion and between one and 10 days after corticosteroid tapering. The latter is done to maintain liver function.
- In March, Novartis said Zolgensma was given to more than 1.8K patients globally.